Search results
Showing 46 to 60 of 151 results for atrial fibrillation
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)
NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .
This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.
Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.
ID NG196/1 Question Tests to diagnose persistent atrial fibrillation: What is the diagnostic accuracy of key index tests (such as the...
Stroke and ischaemic attack: anti-platelet or anticoagulation (IND133)
This indicator covers the percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM94.
Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.
and cost effectiveness of stopping anticoagulation in people whose atrial fibrillation has resolved after ablation? Any explanatory...
Rate-control drug treatment for people aged 75 and over with atrial fibrillation: What is the comparative effectiveness of the 3 main...
View a complete list of indicators currently being developed. Our indicators measure outcomes that reflect the quality of care or processes.
balloon cryoablation in relation to other procedures for treating atrial fibrillation. Further research should define patient selection...
This indicator covers the percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which included: assessment of stroke/VTE risk; assessment of bleeding risk; assessment of renal function, creatinine clearance, FBC and LFTs as appropriate for their anticoagulation therapy; any adverse effects related to anticoagulation; assessment of compliance; choice of anticoagulant. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM147
Irreversible electroporation for treating renal cancer (HTG303)
Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.
View recommendations for HTG303Show all sections
Sections for HTG303
Irreversible electroporation for treating primary lung cancer and metastases in the lung (HTG302)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for HTG302Show all sections
Sections for HTG302
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]
In development Reference number: GID-TA11742 Expected publication date: 05 August 2026
from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?...